机构：[1]Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.[2]Department of Neurology, Xuan Wu Hospital Affiliated to Capital Medical University, Beijing 100053, China.首都医科大学宣武医院[3]Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[4]Department of Neurology, Guangdong General Hospital, Guangzhou 510080, China.广东省人民医院[5]Department of Neurology, Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.苏州大学附属第二医院[6]Department of Neurology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China中山大学附属第一医院[7]Department of Neurology, China‑Japan Union Hospital, Jilin University, Changchun 130031, China吉林大学中日联谊医院[8]Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.[9]Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[10]Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China.内科科室外科科室神经内科泌尿外科昆明医科大学附属第一医院[11]Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.[12]Department of Neurology, Tianjin Huanhu Hospital, Tianjin 300350, China.[13]Institute of Neuroscience, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai 200031, China.[14]Department of Neurology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.[15]Lab for Translational Research of Neurodegenerative Diseases, Shanghai Institute for Advanced Immunochemical Studies (SIAIS), Shanghai Tech University, Shanghai 201210, China.
Background Little is known about the impact of the COVID-19 pandemic on patients with Parkinson's disease (PD) at different stages of the pandemic. This study aims to assess the lives and disease status of PD patients during the zero-COVID policy period and after ending the zero-COVID policy. Methods This multicenter cross-sectional study included two online surveys among PD patients in China, from May 30 to June 30 in 2022 and from January 1 to February 28 in 2023, respectively. The survey questionnaires contained four sections: (1) status of COVID-19 infection; (2) impact on motor and non-motor symptoms; (3) impact on daily and social lives; and (4) impact on PD disease management. Results A total of 1764 PD patients participated in the first online survey, with 200 patients having lockdown experience and 3 being COVID-19-positive (0.17%). In addition, 537 patients participated in the second online survey, with 467 patients having COVID-19 infection (86.96%). (1) During zero-COVID, all of the COVID-19-positive patients had mild symptoms of COVID-19 and no death was reported. After zero-COVID, 83.51% of the COVID-19-positive patients had mild symptoms. The overall death rate and inpatient mortality rate of COVID-19-positive PD patients were 3.21% and 30.00%, respectively. (2) During zero-COVID, 49.43% of PD patients reported worsening of PD-related symptoms (lockdown vs. unlockdown, 60.50% vs. 48.02%, P = 0.0009). After zero-COVID, 54.93% of PD patients reported worsening of PD-related symptoms (COVID-19 positive vs. COVID-19 negative, 59.31% vs. 25.71%, P < 0.0001). (3) During zero-COVID, 62.36% of patients felt worried, and 'limited outdoor activities' (55.39%) was the top reason for mental health problems. After zero-COVID, 59.03% of patients felt worried, with 'poor health' (58.10%) being the top reason. The PD patients tended to change their daily activities from offline to online, and their economic and caregiver burdens increased both during and after zero-COVID. (4) Most PD patients would like to choose online rehabilitation during (69.56%) and after zero-COVID (69.27%). The demand for online medication purchasing also increased during (47.00%) and after zero-COVID (26.63%). Conclusions The COVID-19 pandemic aggravated the motor and non-motor symptoms of PD patients either during or after the zero-COVID policy period. The PD patients also experienced prominent mental health problems, changes in daily activities, and increases in economic and caregiver burdens. The COVID-19 pandemic has changed ways of PD management with increasing demands for online medication purchasing and rehabilitation.
基金：
This work was supported in part by grants from the National Natural Science
Foundation of China (82171401, 81971187, 81971183, 82371414) and Shanghai
Municipal Science and Technology Major Project (2018SHZDZX05).
第一作者机构：[1]Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.[15]Lab for Translational Research of Neurodegenerative Diseases, Shanghai Institute for Advanced Immunochemical Studies (SIAIS), Shanghai Tech University, Shanghai 201210, China.
推荐引用方式(GB/T 7714)：
Huang Pei,Tan Yu-Yan,Chen Biao,et al.Life and disease status of patients with Parkinson's disease during and after zero-COVID in China: an online survey[J].TRANSLATIONAL NEURODEGENERATION.2024,13(1):doi:10.1186/s40035-024-00399-9.
APA：
Huang, Pei,Tan, Yu-Yan,Chen, Biao,Shang, Hui-Fang,Wang, Li-Juan...&Chen, Sheng-Di.(2024).Life and disease status of patients with Parkinson's disease during and after zero-COVID in China: an online survey.TRANSLATIONAL NEURODEGENERATION,13,(1)
MLA：
Huang, Pei,et al."Life and disease status of patients with Parkinson's disease during and after zero-COVID in China: an online survey".TRANSLATIONAL NEURODEGENERATION 13..1(2024)
